Shamburg News · 8-K filed Nov 12, 2026, 4:15 PM EST

Rocket Pharmaceuticals Reports Q3 2026 Net Loss of $49.2 Million, $0.43 Per Share

RCKT · ROCKET PHARMACEUTICALS, INC.

  • Earnings
  • Materiality: high

Rocket Pharmaceuticals, Inc. reported a net loss of $49.2 million, or $0.43 per share basic and diluted, for the quarter ended September 30, 2026, compared with a net loss of $50.3 million, or $0.45 per share, a year earlier. Research and development expenses were $31.2 million and general and administrative expenses were $19.8 million for the quarter. Cash, cash equivalents and investments were $279.4 million as of September 30, 2026, which the company expects to fund operations into the third quarter of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001140361-26-043434.

Written from the filing by Shamburg Markets. Figures are as reported by the company.